Goldman Sachs
FLACW

Goldman Sachs’s Frazier Lifesciences Acquisition Corporation Warrant FLACW Stock Holding History

Goldman Sachs’s Portfolio FLACW Stock Details FLACW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-31,806
Closed -$24K – 6566
2022
Q3 		$24K Sell
31,806
-134,500
-81% -$85.4K ﹤0.01% 5909
2022
Q2 		$13K Sell
166,306
-360
-0.2% -$63 ﹤0.01% 6243
2022
Q1 		$29K Buy
+166,666
New +$72.4K ﹤0.01% 6364

Goldman Sachs's FLACW Position: Q4 2022 in Review

Goldman Sachs sold out of Frazier Lifesciences Acquisition Corporation Warrant (FLACW) in Q4 2022, closing a stake of 31,806 shares — an estimated $24K sold.

Goldman Sachs first reported a position in FLACW in Q1 2022 and held it in 3 quarters. The position peaked at $29K in Q1 2022. 0 funds tracked by Wall St. Rank hold FLACW as of Q4 2022.

  • Goldman Sachs reported no remaining Frazier Lifesciences Acquisition Corporation Warrant position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 31,806 Frazier Lifesciences Acquisition Corporation Warrant shares in Q4 2022, an estimated $24K.
  • Goldman Sachs first reported a position in Frazier Lifesciences Acquisition Corporation Warrant in Q1 2022 and held it in 3 quarters.
  • Goldman Sachs's Frazier Lifesciences Acquisition Corporation Warrant position peaked at $29K in Q1 2022.
  • 0 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Warrant as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.